Details of the Drug Combination

General Information of Drug Combination (ID: DCUOUGJ)

Drug Combination Name

DFN-15 Altretamine

Indication

Disease Entry	Status	REF
Amelanotic melanoma	Investigative	[1]

Component Drugs

DFN-15 DM3BF9B

Altretamine DMKLAYG

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: MDA-MB-435

Zero Interaction Potency (ZIP) Score: 2.01

Bliss Independence Score: 4.58

Loewe Additivity Score: 3.8

LHighest Single Agent (HSA) Score: 1.57

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of DFN-15

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 3	[2]

Indication(s) of Altretamine

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Approved	[3]

Altretamine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
High grade ovarian serous adenocarcinoma	DC0FP06	NCI\\/ADR-RES	Investigative	[1]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
4	Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.